Evaluation of alternate-day valganciclovir prophylaxis for cytomegalovirus disease prevention in moderate risk renal transplant patients: A retrospective observational study

Background: Despite valganciclovir (VGCV) being the recommended agent for Cytomegalovirus (CMV) disease prevention, its optimal dose that maintains parity between the efficacies, toxicity profile, and most importantly, the cost has yet to be established. This study is the first to evaluate alternate...

Full description

Bibliographic Details
Main Authors: Puneet Bhuwania, Ilangovan Veerappan, Ramaswami Sethuraman
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2021-01-01
Series:Indian Journal of Transplantation
Subjects:
Online Access:http://www.ijtonline.in/article.asp?issn=2212-0017;year=2021;volume=15;issue=2;spage=104;epage=110;aulast=Bhuwania